Vector Labs Ab04112-10.3 Anti-OPGL [18B2], Human IgG1, Fc Silent™, kappa (100 μg) Centrifuge Bundle Savings at Sycamore Life Sciences

Description

Product Class: Purified
Clone ID: 18B2
Heavy Chain Modification: Fc Silent™
Synonyms: CD254; Tumor necrosis factor ligand superfamily member 11; TNFSF11; TNF superfamily member 11; Osteoclast differentiation factor; ODF; Osteoprotegerin ligand; OPGL; OPTB2; Receptor activator of nuclear factor kappa-B ligand; RANKL; hRANKL2; TNF-related activation-induced cytokine; TRANCE; sOdf; TNLG6B
Amount: 100 μg
Application Codes Clone: ELISA; SPR; NTRL; in vivo
Shipping Temperature: Wet Ice
Buffer Composition: PBS with 0.02% Proclin 300.
Original Format: IgG1
Storage Temperature: Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Specificity Statement: This antibody is specific for human OPGL. In vivo experiments have shown cross reactivity with Cynomolgus Monkey OPGL.
Application Notes: The binding affinity of this antibody's original format (human IgG1) to hOPGL was confirmed by ELISA. Its binding kinetics to hOPGL 140 and hOPGL 158 was measured by SPR analysis; a K_D of 0.211 nM was measured for hOPGL 140. This antibody was evaluated for its neutralizing activity against osteoclast formation induced by Osteoprotegerin ligand (OPGL) using RAW 264.7 cells, as measured by tartrate-resistant acid phosphatase (TRAP) activity; it inhibited osteoclast formation in a dose-dependent manner with an IC₅₀ of 80 ng/ml. This antibody's pharmacokinetics and in vivo activity were assessed in cynomolgus monkeys — three female cynomolgus monkeys (not greater than five years of age, each weighing between 2 to 5 kgs) received a single subcutaneous dose of 1 mg/kg; serum samples were collected over 56 days to determine the levels of the antibody and analyze bone turnover markers such as serum N-telopeptide (serum N-Tx). The antibody's levels in the serum declined slowly over the testing period; the last measurement on day 56 showed a serum concentration of ~100 ng/ml. Serum N-Tx levels were greatly reduced compared to baseline immediately following injection (~minus 60%), further decreased to a minimum of ~minus 75% over a period of two weeks, after which they began to increase gradually but remained lower in a statistically significant manner than baseline with a final measurement of ~minus 25% on day 56 (US7718776B2).

Product Class:	Purified
Clone ID:	18B2
Heavy Chain Modification:	Fc Silent™
Synonyms:	CD254; Tumor necrosis factor ligand superfamily member 11; TNFSF11; TNF superfamily member 11; Osteoclast differentiation factor; ODF; Osteoprotegerin ligand; OPGL; OPTB2; Receptor activator of nuclear factor kappa-B ligand; RANKL; hRANKL2; TNF-related activation-induced cytokine; TRANCE; sOdf; TNLG6B
Amount:	100 μg
Application Codes Clone:	ELISA; SPR; NTRL; in vivo
Shipping Temperature:	Wet Ice
Buffer Composition:	PBS with 0.02% Proclin 300.
Original Format:	IgG1
Storage Temperature:	Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Specificity Statement:	This antibody is specific for human OPGL. In vivo experiments have shown cross reactivity with Cynomolgus Monkey OPGL.
Application Notes:	The binding affinity of this antibody's original format (human IgG1) to hOPGL was confirmed by ELISA. Its binding kinetics to hOPGL 140 and hOPGL 158 was measured by SPR analysis; a K_D of 0.211 nM was measured for hOPGL 140. This antibody was evaluated for its neutralizing activity against osteoclast formation induced by Osteoprotegerin ligand (OPGL) using RAW 264.7 cells, as measured by tartrate-resistant acid phosphatase (TRAP) activity; it inhibited osteoclast formation in a dose-dependent manner with an IC₅₀ of 80 ng/ml. This antibody's pharmacokinetics and in vivo activity were assessed in cynomolgus monkeys — three female cynomolgus monkeys (not greater than five years of age, each weighing between 2 to 5 kgs) received a single subcutaneous dose of 1 mg/kg; serum samples were collected over 56 days to determine the levels of the antibody and analyze bone turnover markers such as serum N-telopeptide (serum N-Tx). The antibody's levels in the serum declined slowly over the testing period; the last measurement on day 56 showed a serum concentration of ~100 ng/ml. Serum N-Tx levels were greatly reduced compared to baseline immediately following injection (~minus 60%), further decreased to a minimum of ~minus 75% over a period of two weeks, after which they began to increase gradually but remained lower in a statistically significant manner than baseline with a final measurement of ~minus 25% on day 56 (US7718776B2).

Specifications

More Information
Brand	Vector Labs
UNSPSC	12161500

Reviews